Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

MacroChem Accelerates Development of Topical Gel For Impotence LEXINGTON, Mass., April 10, 1997 -- MacroChem Corporation today announced that it is accelerating the product development program of a topical gel containing alprostadil and Sepa(R), for the treatment of erectile dysfunction (impotence). This decision is based on the promising results of the ongoing Phase I/II study. Sepa, MacroChem's proprietary compound, enhances the delivery of drugs through human skin and into the bloodstream. The study was conducted by Kevin McVary, M.D. at Northwestern University Irwin Goldstein, M.D., Professor of Urology at the Boston University School of Medicine, will assist with the scientific and clinical direction of the program. He specializes in the research, diagnosis and treatment of erectile dysfunction, and has published over 150 scientific papers in this area. Dr. Goldstein played a role in the investigation and development of other products for the treatment of erectile dysfunction including Pharmacia & Upjohn's Caverject(R), Pfizer's Viagra(R) and Zonagen's Vasomax(R). MacroChem also announced the appointment of David Ferguson, Ph.D., M.D. as a consultant in clinical development project management. Dr. Ferguson has been involved in pharmaceutical development for 29 years and contributed to 11 successful New Drug Application (NDA) approvals. Since 1992, he has been intimately involved with the design and implementation of clinical programs for urological products, particularly erectile dysfunction. Commenting on the prospects of Sepa/alprostadil, Dr. Ferguson said, if successful, the development of a topical gel alprostadil would have a major impact on this market, as it would be the only drug approved for this indication that would not entail direct injection into the penis (Upjohn's Caverject), or the insertion of a device into the urethra (Vivus' Muse(R)). "Undoubtedly, patients will find a topical gel friendlier to use," he said. He added that currently, impotence affects more than 50% of men over 40 years of age. The next step in the program will be a Phase IIB dose response study to be conducted by Dr. Goldstein. E-mail this page to a friend or colleague! To print, use this version